Research programme: NF-kappa B inhibitors - Othera Pharmaceuticals
Alternative Names: OT 300 programme - Othera Pharmaceuticals; OT-304Latest Information Update: 12 Dec 2012
Price :
$50 *
At a glance
- Originator Othera Pharmaceuticals
- Class Small molecules
- Mechanism of Action NF-kappa B inhibitors; Thromboplastin inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Thrombosis
- Discontinued Rheumatoid arthritis